Physician profile
Peter W Lachiewicz
NPI 1528035912
$1,709.97
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $216 · 2021: $770 · 2022: $290 · 2023: $70.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.16 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $170.31 | 2021 | |
| Avion Pharmaceuticals | $165.07 | 2021-2022 | |
| Minerva Surgical, INC | $150.35 | 2021-2023 | |
| Hologic Sales and Service, LLC | $148.21 | 2019-2020 | |
| Therapeuticsmd, INC. | $97.34 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.08 | 2019-2022 | |
| Pfizer INC. | $73.43 | 2019-2022 | |
| Novo Nordisk INC | $73.21 | 2021-2022 | |
| Daiichi Sankyo INC. | $72.19 | 2020-2021 | |
| Channel Medsystems, INC. | $46.43 | 2022 | |
| Covidien LP | $23.22 | 2020 | |
| Exeltis, USA INC. | $18.68 | 2021 | |
| Allergan, INC. | $15.72 | 2019 | |
| Merck Sharp & Dohme LLC | $15.49 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $13.75 | 2021 | |
| Currax Pharmaceuticals LLC | $13.68 | 2022 | |
| Dysis Medical, INC. | $13.11 | 2021 | |
| Stryker Corporation | $12.54 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lachiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.